Cargando…

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geyer, Holly L., Dueck, Amylou C., Scherber, Robyn M., Mesa, Ruben A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619953/ https://www.ncbi.nlm.nih.gov/pubmed/26538823 http://dx.doi.org/10.1155/2015/284706

Ejemplares similares

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
por: Christensen, Sarah F., et al.
Publicado: (2021)

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
por: Padrnos, Leslie, et al.
Publicado: (2020)

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
por: Langlais, Blake T., et al.
Publicado: (2021)

The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms
por: Gowin, Krisstina, et al.
Publicado: (2020)

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research
por: Huberty, Jennifer, et al.
Publicado: (2019)

Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care
por: Langlais, Blake T., et al.
Publicado: (2020)

Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
por: Christensen, Sarah Friis, et al.
Publicado: (2020)

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase
por: Mendez Luque, Laura F., et al.
Publicado: (2023)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study
por: Win, Hninyee, et al.
Publicado: (2022)

Quality of life and disease understanding: impact of attending a patient-centered cancer symposium
por: Padrnos, Leslie, et al.
Publicado: (2015)

Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research
por: Eckert, Ryan, et al.
Publicado: (2016)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
por: Fleischman, Angela G.
Publicado: (2015)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
por: Koschmieder, Steffen, et al.
Publicado: (2018)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
por: Duncombe, Andrew S., et al.
Publicado: (2020)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Inferring the initiation and development of myeloproliferative neoplasms
por: Hermange, Gurvan, et al.
Publicado: (2022)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study
por: Huberty, Jennifer, et al.
Publicado: (2018)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p3j2lg67o44ds7qseo7lqhn8ai